JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR)

ProQR Therapeutics (NASDAQ:PRQR)‘s stock had its “market outperform” rating restated by analysts at JMP Securities in a report issued on Thursday,Benzinga reports. They currently have a $8.00 target price on the biopharmaceutical company’s stock. JMP Securities’ price objective suggests a potential upside of 182.69% from the company’s current price.

A number of other equities research analysts have also recently weighed in on PRQR. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of ProQR Therapeutics in a research report on Thursday. StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Chardan Capital restated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Thursday. Finally, Raymond James upgraded ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $7.60.

ProQR Therapeutics Trading Down 14.0 %

PRQR stock opened at $2.83 on Thursday. The stock has a market cap of $231.15 million, a P/E ratio of -8.84 and a beta of 0.24. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62. The company’s 50 day moving average is $3.39 and its two-hundred day moving average is $2.38.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. OneDigital Investment Advisors LLC lifted its position in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 15,550 shares during the period. Privium Fund Management B.V. increased its holdings in shares of ProQR Therapeutics by 4.4% in the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after purchasing an additional 236,279 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in shares of ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 7,300 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).